Reduced Ejection Fraction After Recent Bypass: How Strictly to Wait Before a Defibrillator
A single patient whose ejection fraction might still recover, and whose monitor is already showing something that makes waiting to find out feel uncomfortable. The disagreement is about whether the calendar or the telemetry should carry more weight right now.
G.H., a 63-year-old man, is already planning a fishing trip with a few old Navy buddies once he's cleared to travel, a reunion they've talked about for years and finally set a date for this past winter. He underwent coronary artery bypass grafting six weeks ago after presenting with an anterior STEMI, found at the time to have a reduced ejection fraction of 30%, and has prediabetes managed with diet alone. He's recovering well from the surgery itself, but his home monitor has picked up several short runs of nonsustained ventricular tachycardia over the past week, asymptomatic but real.
Guidelines call for a defined waiting period, typically ninety days, after revascularization before reassessing ejection fraction for primary-prevention defibrillator candidacy — a genuinely evidence-based pause, since a meaningful share of patients recover ejection fraction above the device threshold once revascularization and medical therapy have had time to work, and implanting early means committing some of those patients to a device they'll turn out not to have needed. His nonsustained runs don't override that evidence on their own; nonsustained VT in the early post-infarct period is common and doesn't reliably predict who goes on to need a defibrillator. But it's exactly the kind of finding that makes a waiting period feel harder to sit through than it did before anyone was watching for it. His surgical incisions are healing well, and he has otherwise been cleared for the light activity his cardiac rehabilitation team has him doing, which makes the runs on his monitor feel like the one piece of his recovery that still doesn't have a clean explanation attached to it. A wearable cardioverter-defibrillator is the one option that would cover the interval itself rather than argue about it, and it belongs on the table here even though the randomized evidence for it in this window is genuinely mixed.
The calendar or the telemetry
I'd hold to the ninety-day window. Nonsustained VT in the first weeks after a large infarct is common and, on its own, doesn't reliably predict who needs a defibrillator — the guideline waiting period exists precisely because ejection fraction genuinely recovers in a real share of patients with time and optimized therapy, and an early implant commits some of them to a device they won't need.
I follow the evidence on the waiting period generally, but he's not asymptomatic in the way that evidence base assumes — he has real, if brief, runs of ventricular tachycardia we're actually watching happen. I'm less comfortable treating ninety days as a fixed number when there's already something concrete showing up on his monitor that the original recovery data didn't have to account for in every patient.
I'm not proposing we implant today — I'm proposing his interim risk deserves more than "the window will close eventually." Nonsustained runs this early are common, yes, but "common" and "safe to not think about for another seven weeks" aren't quite the same claim.
The real lever available during this waiting period isn't the calendar, it's his medication regimen. Quadruple guideline-directed therapy — a beta-blocker, an ARNI rather than a plain ACE inhibitor, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor — each independently improves ejection fraction on top of whatever recovery revascularization itself provides, and a meaningful fraction of post-MI patients cross back above the device threshold on optimized therapy alone. His nonsustained runs are worth flagging directly to electrophysiology for closer interim monitoring, but the answer to that risk isn't skipping the reassessment window — it's making sure he arrives at day ninety on the most aggressive regimen he can tolerate, not the starting doses from his surgical discharge. One sequencing point that is not optional: he goes home from bypass on an ACE inhibitor, and sacubitril-valsartan cannot be started until that drug has been stopped for a full thirty-six hours. Overlapping them is an angioedema risk the label prohibits outright, and it is the kind of thing that gets lost when a regimen is being rebuilt several drugs at a time.
Quadruple guideline-directed therapy started and uptitrated aggressively during the remainder of the waiting period; his nonsustained VT runs flagged directly to electrophysiology for closer interim telemetry monitoring, without abandoning the ninety-day reassessment window. Ejection fraction to be formally reassessed at that point before any defibrillator decision is made.
Not fully agreed: how much weight his interim ectopy should carry against the waiting period itself. Both physicians left the visit with different comfort levels about the roughly seven weeks still to run, without either treating the other's read as wrong. A wearable cardioverter-defibrillator was raised as the one way to cover that interval directly and left as an open offer rather than a recommendation, given the mixed randomized evidence.